Physician profile
Michael Wilons
NPI 1710983259
$10,425.90
in general payments reported to CMS, 2019-2025
46 companies · $15.96 in 2025
The $15.96 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,169 · 2020: $1,049 · 2021: $1,703 · 2022: $2,101 · 2023: $1,976 · 2024: $1,411 · 2025: $15.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,381 · Education: $22.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,380.80 |
| Education | $22.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,541.53 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals Lp | $1,508.53 | 2019-2024 | Breztri, Airsupra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,366.28 | 2019-2024 | Ofev |
| United Therapeutics Corporation | $582.73 | 2019-2024 | Tyvaso |
| Insmed, INC. | $548.58 | 2019-2024 | Arikayce |
| Genentech USA, INC. | $510.98 | 2019-2023 | Xolair |
| Genzyme Corporation | $418.98 | 2019-2024 | |
| Harmony Biosciences LLC | $363.80 | 2021-2024 | Wakix |
| Novartis Pharmaceuticals Corporation | $342.88 | 2019-2024 | |
| La Jolla Pharmaceutical Company | $342.44 | 2019-2023 | Giapreza |
| Mallinckrodt Hospital Products INC. | $305.53 | 2020-2024 | Acthar |
| Mylan Specialty L.P. | $229.01 | 2019-2024 | Yupelri |
| Merck Sharp & Dohme LLC | $175.14 | 2019-2024 | Zerbaxa, Recarbrio, Winrevair |
| Grifols USA, LLC | $154.15 | 2019 | |
| Philips North America LLC | $146.71 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.